Tempus AI (TEM) said Wednesday its US Food and Drug Administration-approved next-generation sequencing test xT CDx for solid tumor profiling is now available nationwide.
Using a normal-matched approach, where a solid tumor and a normal patient sample are sequenced in parallel, xT CDx can more accurately detect cancer-driving somatic variants, the company said.
All orders for tumor + normal match tests, previously conducted through the company's xT assay, will transition to xT CDx without changing the current ordering workflow, it added.
The company's shares were up 8.9% in recent trading.
Price: 34.67, Change: +2.84, Percent Change: +8.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.